Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
  

EMPLOYMENT AGREEMENT  

        THIS AGREEMENT is made effective as of January 22, 2002, by and between Transgenomic, Inc., a Delaware corporation (the "Company"), and
Keith A. Johnson ("Employee"). 

        The
Company and Employee desire to enter into an Employment Agreement (this "Agreement"). Accordingly, the Company and Employee agree as follows: 

        Section 1.    Effective Date; Position; Term.    This Agreement shall become effective on January 31,
2002 (the "Effective Date"). The Company shall employ Employee as Vice President, General Counsel. The initial term of the Agreement will be for a minimum of three (3) years from the Effective
Date, and the Agreement may be extended upon mutual consent of the parties. 

        Section 2.    Position and Duties.    During the Employment Period: 

        (a)  Employee
shall have the normal responsibilities, duties and authorities of Vice President, General Counsel (Attached hereto as Exhibit B.) 

        (b)  Employee
shall report to the Executive Vice President of the Company and Employee shall perform faithfully the executive duties assigned to him to the best of his
ability in a diligent, trustworthy, businesslike and efficient manner and will devote his full business time and attention to the business and affairs of the Company and its Subsidiaries and
Affiliates; provided, however, that Employee may serve as a director of or a consultant to other corporations which do not compete with the Company, nonprofit corporations, civic organizations,
professional groups and similar entities. 

        (c)  For
purposes of this Agreement, "Subsidiary" shall mean any corporation or other entity of which securities having a majority of the voting power in electing directors
or comparable management are, at the time of determination, owned by the Company, directly or through one or more Subsidiaries. 

        (d)  For
purposes of this Agreement, "Affiliate" of any particular person means any other person controlling, controlled by or under common control with such particular
person. 

        Section 3.    Basic Compensation.

        (a)  Base Salary. As compensation for his services hereunder, the Company shall pay to Employee during the Employment Period
an initial base salary of $135,000 per year. 

        Base
Salary shall be payable in equal installments in arrears on a biweekly basis or as otherwise may be mutually agreed upon. 

        The
salary shall be increased over the previous year's salary as is mutually agreed to. 

        Section 4.    Participation in Employee Benefit Plans.    Employee will be entitled to participate in all
Company salaried employee benefit plans and programs, subject to the terms and conditions of each such employee benefit plan or program and to the extent commensurate with his position as Vice
President, General Counsel. 

        Section 5.    Other Benefits.

	(a)
	Vacation. Employee shall initially be entitled to three weeks' paid vacation each year.

	(b)
	Insurance. The Company shall make available to Employee life, health and dental insurance (including
dependent coverage), and other benefits from time to time provided to employees.

	(c)
	Relocation. The Company during the initial term of this Agreement shall pay for or reimburse Employee
for all costs reasonably related to relocation, including, but not limited to, travel expenses, moving expenses, real estate commissions and real estate closing costs. 

        Section 6.    Business Expenses.    The Company shall reimburse Employee for all reasonable expenses incurred
by him in the course of performing his duties under this Agreement which are consistent with the Company's policies in effect from time to time with respect to travel, entertainment and other business
expenses, subject to the Company's requirements with respect to report and documentation of such expenses. The Company shall pay for or reimburse Employee for all expenses necessary to maintain
Employee's professional qualifications as General Counsel including, but not limited to, bar examination fees, preparatory courses, state bar fees, expense for continuing legal education, and
reasonable expenses for memberships in professional organizations. 

        Section 7.    Stock Options and Option Shares.    Employee will initially be granted 35,000 shares subject to
the approval of the Compensation Committee of the Board of Directors. The price of the options will be the fair market value on the date the options are granted. Twenty five percent (25%) of the
options will vest immediately on the date of the grant, the remaining options will vest twenty five percent (25%) on the next three anniversary dates of the date of the grant. All unvested options
will vest upon the Company being acquired or merged into another entity. 

        Section 9.    Termination of Employment.

        (a)  Events of Termination and Severance Payment. In the event that, during the term of this Agreement, Employee is discharged
for any reason other than for Just Cause (as defined below), Employee shall be entitled to receive certain payment (the "Severance Payment") following termination of employment. Severance Payment will
be made at the Employees then current base salary for an amount equal to 12 (twelve) months' salary. In addition, in case of such discharge, Employee will retain all vested stock options. All unvested
stock options will lapse. 

        (b)  "Just
Cause" being defined as any criminal act (felony) being committed by employee, if employee commits fraud or dishonesty toward the Company, other significant
activities materially harmful to the reputation of the Company as reasonably defined by the Company, willful refusal to perform or substantial disregard of the duties properly assigned, significant
violation of any statutory or common law or a material violation of Section 11 or 12 below, or intentionally takes any other action materially inimical to the best interests of the Company 

        (c)  Effect of Breach of Noncompetition Provisions. In the event Employee breaches or otherwise fails to comply with the
provisions of Section 11 or 12 below, then, in addition to any other remedies provided herein or at law or in equity, the Company shall have the right to require return of any severance payment
made to the Employee. Return of such Severance Payment pursuant to the preceding sentence shall not relieve Employee's obligations pursuant to Section 11 or 12 below. 

        Section 10.    Assignment and Succession.

        (a)  The
rights and obligations of the Company under this Agreement shall inure to the benefit of and be binding upon its respective successors and assigns, and Employee's
rights and obligations hereunder shall inure to the benefit of and be binding upon his successors and permitted assigns, whether so expressed or not. 

        (b)  Employee
acknowledges that the services to be rendered by him hereunder are unique and personal. Accordingly, Employee may not pledge or assign any of his rights or
delegate any of his duties or obligations under this Agreement without the express prior written consent of the Company. 

        (c)  The
Company may not assign its interest in or obligations under this Agreement without the prior written consent of Employee. 

        Section 11.    Confidential Information.

        (a)  Company Information. Employee agrees at all times during the term of his Relationship with the Company and thereafter, to
hold in strictest confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm, corporation or other entity without 

written authorization of the Board of Directors of the Company, any Confidential Information of the Company which Employee obtains or creates, by whatever means. Employee further agrees not to make
copies of such Confidential Information except as authorized by the Company. Employee understands that "Confidential Information" means any Company
proprietary information, technical data, trade secrets or know-how, including, but not limited to, research. product plans, products, services, suppliers, customer lists and customers
(including, but not limited to, customers of the Company on whom Employee called or with whom Employee became acquainted during the Relationship), prices and costs, markets, software, developments,
inventions, laboratory notebooks, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, budgets or other business
information disclosed to Employee by the Company either directly or indirectly in writing, orally or by drawings or observation of parts or equipment or created by Employee during the period of the
Relationship, whether or not during working hours. Employee understands that "Confidential Information" includes, but is not limited to, information
pertaining to any aspects of the Company's business which is either information not known by actual or potential competitors of the Company or is proprietary information of the Company or its
customers or suppliers, whether of a technical nature or otherwise. Employee further understands that "Confidential Information" does not include any of
the foregoing items which have become publicly and widely known and made generally available through no wrongful act of Employee's or of others who were under confidentiality obligations as to the
item or items involved. 

        (b)  Former Employer Information. Employee represents that as an employee of the Company, he has not breached and will not
breach any agreement to keep in confidence proprietary information, knowledge or data acquired by Employee in confidence or trust prior or subsequent to the commencement of Employee's Relationship
with the Company, and Employee will not disclose to the Company, or induce
the Company to use, any inventions, confidential or proprietary information or material belonging to any previous employer or any other party. 

        (c)  Third Party Information. Employee recognizes that the Company has received and in the future will receive confidential or
proprietary information from third parties subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. Employee agrees
to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out
Employee's work for the Company consistent with the Company's agreement with such third party. 

        Section 12.    Return of Company Documents.    Employee agrees that, at the time of termination of his
Relationship with the Company, he will deliver to the Company (and will not keep in his possession, recreate or deliver to anyone else) any and all devices, records, data, notes, reports, proposals,
lists, correspondence, specifications, drawings, blueprints, sketches, laboratory notebooks, materials, flow charts; equipment, other documents or property, or reproductions of any aforementioned
items developed by Employee pursuant to the Relationship or otherwise belonging to the Company, its successors or assigns. Employee further agrees that any property situated on the Company's premises
and owned by the Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company personnel at any time with or without notice. In the event
of the termination of the Relationship, Employee agrees to sign and deliver the "Termination Certification" attached hereto as Exhibit "A." 

        Section 13.    Noncompetition.    Independent of any obligation under any other contract or agreement between
Employee and the Company, for a period of one (1) year following the termination of Employee's employment relationship with the Company, Employee shall not, directly or indirectly, whether as
an individual for his own account, or for or with any other person, firm, corporation, partnership, joint venture, association, or other entity whatsoever, which is or intends to be engaged in
biotechnology business and, more particularly, that provides technologies for DNA/RNA analysis and purification utilization DHPLC technologies (provided, however, that the restrictions set forth in
this clause shall not apply to involvement that consists solely of "beneficially owning," as such term is used 

in Rule 13d-3 promulgated under the Exchange Act 2% or less of the outstanding securities of any class of securities issued by a publicly-traded entity): 

        (a)  Solicit,
interfere with, or endeavor to entice away from the Company, any person, firm, corporation, partnership, or entity of any kind whatsoever, which was or is a
client or licensor of the Company, for which the Company performed services, with respect to any business, product or service that is competitive to the products or services offered by the Company, or
under development by the Company, as of the date of the termination of Employee's relationship with the Company. This restriction shall apply only to such clients or licensors of the Company as were
serviced or solicited by Employee at any time during the one (1) year prior to the separation of Employee's relationship with the Company, either as an independent contractor or as an employee
of the Company; 

        (b)  Solicit
or endeavor to induce any of the Company's employees or consultants to terminate their relationship with the Company, or take away such employees or consultants,
or attempt to solicit, induce, recruit, encourage or take away employees or consultants of the Company, either for Employee or for any other person or entity; 

        (c)  Induce
or attempt to induce any supplier, licensee or other business relation of the Company to cease doing business with the Company, or in any way interfere with the
relationship between any such supplier, licensee or business relation and the Company. 

        Section 14.    Business Opportunity.    Employee represents and acknowledges that the foregoing restrictions
will not prevent him from obtaining gainful employment in his field of expertise or cause him undue hardship; and that there are numerous other employment opportunities available to him that are not
affected by the foregoing restrictions. Employee further acknowledges that the foregoing restrictions are reasonable and necessary, in order to protect the Company's legitimate interests, and that any
violation thereof would result in irreparable injury to the Company. 

        Section 15.    Conflicts of Interest Policies.    Employee shall diligently adhere to the Company's Conflict of
Interest Policy as adopted by the Board and in effect from time to time. 

        Section 16.    Arbitration and Equitable Remedies.

        a)    Except
as provide in Section 16 (b) hereof, the parties agree that any dispute or controversy arising out of, relating to, or concerning the interpretation,
construction, performance or breach of this Agreement, shall be settled by arbitration to be held in Nebraska, in accordance with the Employment Dispute Resolution rules of the American Arbitration
Association then in effect. The arbitrator may grant injunctions or other relief in such dispute or controversy and the decision of the arbitrator shall be final, conclusive and binding on the parties
to the arbitration. Judgment may be entered on the arbitrator's decision in any court having jurisdiction. The Company and Employee shall each pay one-half of the costs and expenses of
such arbitration, and each shall separately pay the fees and expenses of their respective legal counsel. 

        THIS
ARBITRATION CLAUSE CONSTITUTES A WAIVER OF EMPLOYEE'S RIGHT TO A JURY TRIAL AND RELATES TO THE RESOLUTION OF ALL DISPUTES RELATING TO ALL ASPECTS OF THE EMPLOYER/EMPLOYEE
RELATIONSHIP. 

        (b)  Notwithstanding
paragraph (a) of this Section 16, the parties agree that, in the event of the breach or threatened breach of Sections 11, 13 or 14 of this
Agreement by Employee, monetary damages alone would not be an adequate remedy to the Company and its Subsidiaries for the injury that would result from such breach, and that the Company and its
Subsidiaries shall be entitled to apply to any court of
competent jurisdiction for specific performance and/or injunctive relief (without posting bond or other security) in order to enforce or prevent any violation of such provisions of this Agreement.
Employee further agrees that any such injunctive relief obtained by the Company or any of its Subsidiaries shall be in addition to monetary damages. 

        Section 17.    Indemnification.    The Company agrees to indemnify and hold harmless Employee for any and all
actions taken by Employee in carrying out his duties under this Agreement. 

        Section 18.    Entire Agreement.    This Agreement represents the entire agreement between the parties relating
to the subject matters covered hereby and shall supersede any prior understandings, agreements or representations by or between the parties, written or oral, which may have related to the subject
matter hereof in any way and shall not be amended or waived except in a writing signed by the parties hereto. 

        Section 19.    Notices.    Any notice or request required or permitted to be given hereunder shall be in
writing and will be deemed to have been given (i) when delivered personally, sent by telecopy (with hard copy to follow) or overnight express courier or (ii) five days following mailing
by certified or registered mail, postage prepaid and return receipt requested, to the addresses below unless another address is specified by such party in writing: 

	To the Company:	Transgenomic, Inc.

12325 Emmet Street

Omaha, NE 68164

Attention: Chief Executive Officer

Telephone: (402) 452-5433

Telecopy: (402) 452-5447
	

To the Employee:	

Keith A. Johnson

48 Farms Road Circle

East Brunswick, NJ, 08816

        Section 20.    Headings.    The article and section headings herein are for convenience
of reference only and shall not define or limit the provisions hereof. 

        Section 21.    Applicable Law.    The corporate law of the State of Delaware will govern all questions
concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity and interpretation of this Agreement shall be governed by the internal
laws of the State of Nebraska. 

        Section 22.    Severability.    Whenever possible, each provision of this Agreement will be interpreted in such
manner as to be effective and valid under applicable law, but if any provision of this Agreement is held prohibited by, invalid or unenforceable in any respect under applicable law, such provision
will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 

        Section 23.    Amendments and Waivers.    Any provision of this Agreement may be amended or waived only with
the prior written consent of the Company and Employee. 

        Section 24.    No Strict Construction.    The language used in this Agreement will be deemed to be the language
chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party hereto. 

        Section 25.    Counterparts.    This Agreement may be executed in separate counterparts, each of which is
deemed to be an original and all of which taken together constitute one and the same agreement. 

        Section 26.    Employee Representations.    Employee hereby represents and warrants to the Company that
(i) the execution, delivery and performance of this Agreement by Employee does not and will not conflict with, breach, violate or cause a default under any contract, agreement, instrument,
order, judgment or decree to which Employee is a party or by which he is bound, (ii) Employee is not a party to or bound by any employment agreement, noncompete agreement or confidentiality
agreement with any other person or entity, other than as disclosed with Integra LifeSciences Corporation, and 

(iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Employee, enforceable in accordance with its terms. 

        Section 27.    Survival.    Sections 8, 11, 12 and 15 shall survive and continue in full force in
accordance with their terms notwithstanding any termination of the Employment Period. 

        IN
WITNESS WHEREOF, the Company has caused this Agreement to be signed by its duly authorized officer and Employee has signed this Agreement. 

	 	TRANSGENOMIC, INC.
	

 	

By	

/s/  COLLIN J. D'SILVA      

	 	 	Name:	 	Collin D'Silva
	 	 	Title:	 	Chief Executive Officer
	

 	
EMPLOYEE
	

 	

/s/  KEITH A. JOHNSON      
 Name: Keith A. Johnson

QuickLinks

Exhibit 10.1QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.2    
  

	**
	Certain
Confidential portions of this Exhibit were omitted by means of redacting a portion of the text indicated by two asterisks "**". This Exhibit has been filed separately with the
Secretary of the Commission without the ** pursuant to the Registrant's Application Requesting Confidential Treatment under Rule 24b-2 of the Securities Exchange Act. 

TERM LOAN AGREEMENT  

        THIS TERM LOAN AGREEMENT (this "Agreement") is dated and effective as of February 1, 2002 by and between
TRANSGENOMIC, INC., a corporation organized under the laws of the State of Delaware U.S.A. (the "Lender"), and GENODYSSEE S.A., a  société
anonyme organized under the laws of France, with a share capital of 65,122 euros, having its registered office at
Parc Affaires Technopolis, 3, avenue du Canada, BP 810 Les Ulis, 91974 Courtaboeuf, France and registered with the Registre du Commerce et des
Sociétés of Evry under number 424 796 548 (the "Borrower"). The Lender and the
Borrower are sometimes collectively referred to herein as the "parties" and individually as a "party." 

PREAMBLE  

        WHEREAS, the Lender has agreed to lend to the Borrower, on the terms and conditions set forth herein, an amount of One Million Five Hundred Thousand U.S. Dollars
(US $1,500,000) (the "Loan") which Loan will be evidenced by that certain promissory note, of even date herewith, made by the Borrower to the Lender, in
the form attached as Exhibit A hereto (the "Note"); and 

        WHEREAS,
the parties desire to set forth certain terms and conditions relating to the Loan; 

        NOW,
THEREFORE, in consideration of the mutual covenants, promises, representations and warranties set forth herein, the parties agree as follows: 

ARTICLE I

DEFINITIONS  

        All capitalized terms used in this Agreement shall have the following meanings (such meanings to be equally applicable to both the singular and the plural forms
of the terms defined): 

        "Agreement" shall mean this Term Loan Agreement, including all exhibits hereto, as the same may be amended or otherwise modified from time
to time. 

        "Business Day" shall mean a day other than a Saturday, Sunday or other day on which commercial banks are authorized or required to close
under the laws of the United States of America or the Republic of France. 

        "Default" shall mean any of the events specified in Section 6.01, without giving effect to any requirement for the giving of
notice, for the lapse of time, or both, or for the happening of any other condition, event or act. 

        "Event of Default" shall mean any of the events specified in Section 6.01, provided that any requirement for the giving of notice,
the lapse of time, or both, or for the happening of any further condition, event or act has been satisfied. 

        "Governmental Authority" shall mean any government (whether the located within or outside the United States or France) or any department,
agency, division or instrumentality thereof. 

        "Law" shall mean any statute, rule, regulation, order, judgment, award or decree of any Governmental Authority. 

        "Major Shareholders" shall mean those holders of the Borrower's ordinary voting shares that together hold not less than 66.667% of
Borrower's issued and outstanding share capital. 

 

        "Person" shall mean and include an individual, a partnership, a corporation, a trust, an unincorporated association, a joint venture or
any other entity or a government or any agency or political subdivision thereof. 

        "Principal Balance" shall mean U.S.$ 1,500,000, as reduced from time to time by the amount of any prepayment made by the Borrower. 

        All
monetary amounts expressed herein are stated in terms of U.S. Dollars. 

ARTICLE II

THE LOAN  

        Section 2.01. Loan Disbursement.    Upon execution and delivery to Lender of this Agreement and the undertaking of the
Major Shareholders described in Section 4.03 hereof, the Lender agrees to advance U.S. $1,500,000 to the Borrower. The disbursement of the Loan proceeds shall be made by direct wire transfer of
funds from the Lender no later than February 10, 2002 to the account of the Borrower at the **. 

        Section 2.02. Use of Proceeds.    The Loan shall be applied by the Borrower for general corporate purposes. 

ARTICLE III

INTEREST  

        Section 3.01. Interest Rate.    The Borrower shall pay interest on the unpaid principal balance of the Loan at the rate
of 5.0% per annum from the date of issuance of the Loan proceeds thereof to and including the date of repayment. 

        Section 3.02. Computation.    Interest on the Loan shall be computed on the basis of a year deemed to consist of
365 days and paid for the actual number of days elapsed. 

ARTICLE IV

PAYMENTS  

        Section 4.01. Interest Payments.    Accrued but unpaid interest on the outstanding Principal Balance of the Loan shall be
due and payable in full, without demand by the Lender, immediately (i) upon repayment of the Principal Balance as provided herein, (ii) with respect to any full or partial prepayment of
the Principal Balance as described under section 4.05 hereof, at the time of such prepayment. 

        Section 4.02. Principal Payments.    The Principal Balance shall be paid in full on the earlier of
(i) 3:00 p.m. GMT on January 31, 2003 (the "Maturity Date") or (ii) the first closing date on which new voting equity
securities in the Borrower are subscribed pursuant to a private or public offering thereof that raises gross proceeds (prior to the payment of any underwriters' commissions or discounts and other
offering expenses) of not less than US $5,000,000 (a "Qualified Offering"). The Borrower shall give notice of any Qualified Offering to the Lender,
including all material terms of such proposed issuance, at least 25 Business Days prior to the consummation thereof. 

Section 4.03. Repayment by means of issuance of Equity Securities.  

        (a)  The
Principal Balance of, and accrued interest on, the Loan will be repaid by the Borrower through the issuance of newly issued voting equity securities to the Lender as
provided in Section 4.02 and this Section 4.03, subject to (i) the certification of the amount of the Principal Balance of, and accrued interest on the Loan by the statutory
auditors of the Borrower and (ii) approval of the necessary capital increase at an extraordinary general meeting of the shareholders of the Borrower in 

2

 

accordance with French law. If a Qualified Offering is proposed prior the Maturity Date, the Borrower will use its commercially reasonable efforts to cause the capital increase required in order to
issue securities to the Lender to be submitted to the vote of the shareholders of the Borrower at the same extraordinary general meeting as the Qualified Offering. As such, the Borrower shall use its
commercially reasonable efforts to have such capital increase put on the agenda of such general meeting by its board of directors convening it and to have such capital increase in favor of the Lender
voted on by its shareholders in accordance with French law. In the event that a Qualified Offering is not consummated prior to the Maturity Date, the Borrower shall use its commercially reasonable
efforts to have an extraordinary general meeting convened by its board of directors prior the end of March 31, 2003, with a capital increase in favor of the Lender on its agenda and to have the
said capital increase in favor of the Lender voted on by its shareholders in accordance with French law. As a condition to the advancement of funds by the Lender to the Borrower hereunder, the
Borrower shall obtain from the Major Shareholders an irrevocable undertaking in the form attached as Exhibit B hereto. 

        (b)  If
a Qualified Offering is consummated prior the Maturity Date, the voting equity securities of the Borrower issued in repayment of the Principal Balance of, and
interest on, the Loan will be of the same type and class as those issued in the Qualified Offering and on the same terms and conditions (including, but not limited to, price per share) as such
securities issued to investors in the Qualified Offering. 

        (c)  In
the event that a Qualified Offering is not consummated prior to the Maturity Date, the voting equity securities of the Borrower issued in repayment of the Principal
Balance of, and interest on, the Loan will be ordinary voting shares and will be issued at a price per share determined by an appraisal of the Borrower conducted by an independent qualified investment
banking firm agreed to by the Borrower and the Lender. In such event, the Lender will be entitled to such rights, including but not limited to, rights of co-sale, rights of first offer,
rights of first refusal, registration rights, and voting rights, as the Major Shareholders are granted pursuant to the shareholders' agreement dated September 8, 2000. 

        (d)  In
the event that the shareholders of the Borrower do not vote at any general meeting of shareholders described in this Section 4.03 in favor of the necessary
capital increase to the benefit of the Lender, the Loan will be required to be repaid in cash at the Maturity Date (or such later date as provided in Section 4.03(a), but in no event later than
February 28, 2003). 

        (e)  In
the event of a repayment after the Maturity Date as permitted pursuant to this Section 4.03, so long as there has otherwise been no Event of Default, interest
shall continue to accrue at the rate set forth in Section 3.01 until and including the date of repayment. 

        Section 4.04. Due Dates Not on Business Days.    If payment required hereunder becomes due on a date that is not a
Business Day, then such due date shall be deemed to be the next following Business Day. 

        Section 4.05. Right to prepay.    The Borrower shall have the right, in its sole discretion, to prepay in cash, in whole
or in part, the Principal Balance of the Loan at any time, without any penalty. 

ARTICLE V

COVENANTS, REPRESENTATIONS AND ACKNOWLEDGEMENTS  

        Section 5.01. Affirmative Covenants.    During the term of this Agreement, the Borrower covenants and agrees as follows: 

        (a)  Board Seat. The Borrower undertakes to use its commercially reasonable efforts to have its  statuts (by-laws) or any shareholders' agreement relating to its shares
amended in order to entitle the Lender to appoint one member of the
Borrower's Board of Directors (it being understood by the 

3

 

parties that such actions may be taken only by the shareholders of the Borrower under French Law) but only if the Loan is repaid through the issuance of voting equity securities in accordance with
Article IV hereof and then only for so long as the equity securities held by the Lender represent at least 10% of the Borrower's issued and outstanding voting securities. 

        (b)  Qualified Offering. The Borrower shall use its commercially reasonable best efforts to conduct a Qualified Offering prior
to the Maturity Date, it being understood that the approval required to conduct such capital increase may only be obtained by a vote of the Borrowers' shareholders at a general meeting of
shareholders. 

        (c)  Corporate Existence and Authorizations. The Borrower shall maintain in good standing its corporate existence and its
right to transact business in those jurisdictions in which it is now or hereafter doing a material amount of business, and the Borrower shall maintain all material licenses, permits and registrations
necessary for the conduct of its operations. 

        (d)  Compliance With Laws. The Borrower shall comply with all material Laws applicable to its business operations. 

        (e)  Payment of Obligations. The Borrower shall promptly pay and discharge or cause to be paid and discharged, as and when due
(or as amended or extended by the lender or creditor), any and all of its lawful debts and other obligations, including all lawful taxes, rates, levies and assessments and all claims for labor,
materials or supplies; provided, however, that nothing herein contained shall be construed as prohibiting the Borrower from diligently contesting in good faith by appropriate proceedings the validity
of any such debt or other obligation, provided Borrower has established adequate reserves for such debt or obligation on its books and records. 

        (f)    Financial Information. The Borrower will provide the Lender with copies of its audited financial statements for the year
ending December 31, 2001 as soon as reasonably practicable after such financial statements are available, but in no event later than March 31, 2002. The Borrower will provide the Lender
with unaudited quarterly financial statements within 45 days of the end of each calendar quarter ending prior to repayment of the Loan. 

        (g)  Securities Offering Documents. The Borrower will provide the Lender with copies of all documents prepared by the Borrower
in connection with the private or public offering of any equity or debt securities prior to the Maturity Date as soon as reasonably practicable after such documents are available. 

        Section 5.02. Negative Covenants.    During the term of this Agreement, the Borrower covenants and agrees, that without
the prior written consent of the Lender: 

        (a)  Dividends. The Borrower shall not declare or pay dividends or other distributions to its existing shareholders or other
equity owners. 

        (b)  Use of Proceeds. The Borrower will not use the proceeds of the Loan to be used for any purpose other than that stated
herein. 

        (c)  Conflicting Agreements. The Borrower will not enter into any agreement, any term or condition of which would, if complied
with by Borrower, result in an Event of Default. 

        Section 5.03. Representations and Acknowledgements of Lender.    In connection with the potential issuance of securities
of the Borrower in repayment of the Loan pursuant to Article IV hereof: 

        (a)  the
Lender represents that it is an "accredited investor" as defined in Regulation D of the U.S. Securities Act of 1933 (the "Securities
Act"); and 

        (b)  the
Lender acknowledges that (i) such securities have not and will not be registered under the Securities Act, (ii) that the securities will be "restricted
securities" for purposes of the Securities Act 

4

 

and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except (A) in compliance with the registration requirements of the Securities Act
and all other applicable securities laws or (B) pursuant to an exemption from or a transaction not subject to the
registration requirements of the Securities Act or any other applicable securities laws; (iii) the foregoing will be deemed to be repeated by the Lender at the time of the issuance of the
securities; and (iv) securities issued to the Lender will be notated with the foregoing transfer restrictions on the books of the Borrower. 

ARTICLE VI

DEFAULT  

        Section 6.01. Events of Default.    Any one or more of the following shall constitute an Event of Default under this
Agreement, unless waived by the Lender: 

        (a)  Payment. Failure to pay principal or interest when due and payable under the Note, or failure to pay any other material
indebtedness for borrowed money of the Borrower, including the $1,000,000 revolving line of credit made available by Lender to Borrower under that certain Revolving Line of Credit Agreement, dated as
of December 28, 2001 (the "Line of Credit"), which continues beyond any applicable grace period or negotiated extension. 

        (b)  Breach of Covenants. The material breach of any covenant in Article VI unless expressly waived, in writing, by the
Lender, which breach is not cured within 30 Business Days. 

        (c)  Acceleration of Other Indebtedness. Any obligation of the Borrower (including the Line of Credit) for the payment of
borrowed money becomes or is declared to be due and payable or required to be prepaid (other than by a regularly scheduled prepayment) prior to the expressed maturity thereof and the Borrower has not
cured the default giving rise to such an acceleration within 30 Business Days. 

        (d)  Judgments; Attachment; Etc. Any one or more judgments or orders against the Borrower or any attachment or other levy
against the property of the Borrower with respect to a claim or claims, involving in the aggregate liabilities (not paid or fully covered by insurance, less the amount of reasonable deductibles) in
excess of $500,000, remains unpaid, unstayed on appeal, undischarged, unbonded or undismissed for a period of 30 Business Days. 

Section 6.02. Rights and Remedies in the Event of Default.  

        (a)  Upon
any Event of Default, and at any time thereafter, the Lender may declare in writing to the Borrower all or any part of the outstanding Principal Balance and accrued
interest thereon immediately due and payable, and upon such declaration the then outstanding Principal Balance and such accrued interest shall automatically become immediately due and payable. 

        (b)  If,
within 15 Business Days of a valid declaration by the Lender as set forth in clause 6.02(a) above the relevant default has not been cured by the Borrower (if
capable of being cured), the Lender shall be entitled to exercise any or all of the rights of the Lender under this Agreement. 

        (c)  Any
funds received by the Lender with respect to the Loan shall be applied as follows: (i) first, to the payment of the reasonable and necessary expenses incurred
by Lender in connection with the collection of amounts due hereunder, not to exceed US$50,000; (ii) second, to the payment of interest accrued and unpaid on the Loan; and (iii) third, to
the payment of outstanding Principal Balance. Any remaining amounts shall be paid to the Borrower. 

        (d)  At
the option of the Lender, the Borrower shall pay interest on (i) all amounts overdue by more than five Business Days and (ii) all amounts due by the
Borrower, whether mature or not, after the occurrence of an Event of Default (until such time as the Event of Default may be cured), at a rate 

5

 

equal to the greater of (x) 7.0% per annum or (y) the prime interest rate prevailing in the United States as of the date of the Event of Default, as published in the  Wall Street Journal.

        Section 6.03. Remedies not Exclusive.    The Lender shall be entitled to enforce payment and performance of all
obligations of the Borrower hereunder or under the Note and to exercise all rights and powers hereunder or under the Note, or under any Law and the pursuit of any remedy available to the Lender
against the Borrower shall not prejudice or in any manner affect the Lender's right to realize upon or enforce any other remedy or security now or hereafter available to it in such order and in such
manner as the Lender may determine in its sole discretion. No such right or remedy shall be exclusive, but each shall be cumulative and shall be in addition to every other remedy provided herein or in
any other agreement or by Law and each such remedy may be exercised concurrently or independently. Nothing in this Agreement shall be construed as prohibiting the Lender from seeking a deficiency
judgment against the Borrower. 

ARTICLE VII

MISCELLANEOUS  

        Section 7.01. Notices.    All notices or other communications to be given hereunder shall be given in writing and
delivered by (a) certified mail, return receipt requested, (b) personal delivery, (c) facsimile or (d) express carrier addressed as follows: 

	If to the Lender:	Transgenomic, Inc.

12325 Emmet Street

Omaha, Nebraska 68164

U.S.A.

Attention: Gregory J. Duman

Email: gduman@transgenomic.com

Telephone: (402) 452-5400

Telecopy: (402) 452-5447
	

If to the Borrower:	

Genodyssee S.A.

Parc Affaires Technopolis

3, avenue du Canada—Bâtiment Alpha

BP 810 Les Ulis—91974 Courtaboeuf Cedex

France

Attention: Jean-Louis Escary

Email: escary@genodyssee.com

Telephone: (33) (0) 1 69 29 80 55

Telecopy: (33) (0) 1 69 29 80 79

or to such other address furnished by any party to the other in writing at any time and from time to time for such notice purposes. Any notice served by either party on the
other shall be deemed effective upon receipt of return receipt if sent by certified mail, return receipt requested, when received, if delivered personally, upon machine confirmation if sent by
facsimile, or upon confirmation of delivery by an express carrier. 

        Section 7.02. Amendments and Waivers.    No amendment, modification or waiver of any provision of this Agreement or the
Note shall be effective unless the same shall be in writing and signed by the Borrower and the Lender; provided, however, that any such waiver or consent shall be effective only in the specific
instance and for the purpose for which given. 

6

 

        Section 7.03. Successors and Assigns.    Neither the Borrower nor the Lender may assign, delegate or transfer any of its
rights or obligations under this Agreement or the Note without the prior written consent of the other. 

        Section 7.04. Severability.    If any provision of this Agreement is held invalid or unenforceable, or which is
prohibited under Law for any reason, the invalidity shall not affect the validity of the remaining provisions of this Agreement, and the parties shall substitute for the invalid provision a valid
provision which most closely approximates the intent and economic effect of the invalid provision. 

        Section 7.05. Counterparts.    This Agreement may be executed by the parties hereto on any number of separate
counterparts, and all such counterparts taken together shall constitute one and the same instrument. It shall not be necessary in making proof of this Agreement to produce or account for more than one
counterpart signed by the party to be charged. 

Section 7.06. Governing Law; Arbitration; No Third-Party Rights.  

        (a)  This
Agreement and the rights and obligations of the parties hereunder shall be governed by and construed and interpreted in accordance with the laws of the United
States and State of New York applicable to contracts made and to be performed wholly within such State, without regard to any choice or conflict of laws rules. Notwithstanding the foregoing, any
issuance of equity securities of the Borrower to the Lender hereunder shall be governed by French law. 

        (b)  The
parties to this Agreement shall act in good faith to resolve any dispute or other controversy arising under this Agreement. Absent agreement resolving a dispute
within 20 days after written notice of the dispute has been delivered from one party to the other, any party shall have the right to seek to settle the matter by arbitration to the exclusion of
any other form of dispute resolution. Any arbitration shall be conducted according to the applicable rules of the American Arbitration Association and shall take place in New York, New York. Such
arbitration shall be heard by a single arbitrator, who shall be jointly designated by the Lender and the Borrower if the parties are unable to agree within ten (10) days after the dispute is
submitted to arbitration, by the American Arbitration Association. The decision of the arbitrator shall be final and binding upon the parties hereto. The each party in any arbitration proceeding shall
pay its own costs in connection therewith, including attorneys' fees. 

        (c)  This
Agreement is solely for the benefit of the parties hereto and their respective successors and assigns, and no other Person shall have any right, benefit, priority
or interest under, or because of the existence of, this Agreement. 

        Section 7.07. Headings.    The section headings are for convenience only and shall not affect the interpretation or
construction of this Agreement or the Note. The Exhibits referred to throughout this Agreement are attached to this Agreement and are incorporated into this Agreement. Unless the
context clearly indicates, words used in the singular include the plural, words in the plural include the singular and the word "including" means "including but not limited to." 

        Section 7.08. The Lender's Sole Discretion.    Any provision in any of this Agreement or the Note which requires the
Lender's approval or consent shall be interpreted to mean at the Lender's sole discretion unless otherwise specified. 

        Section 7.09. Conflict of Terms.    In the event of any material conflict between the terms of this Agreement and the
Note, the terms of this Agreement shall control. 

        Section 7.10. Waiver.    The failure of either party at any time to require performance by the other party of any
provision of this Agreement shall not affect in any way the full right to require the performance at any subsequent time. The waiver by either party of a breach of any provision of this 

7

 

Agreement shall not be taken or held to be a waiver of the provision itself. Any course of performance shall not be deemed to amend or limit any provision of this Agreement. 

        Section 7.11. Section References.    References to "Sections," "subsections" and "Exhibits" shall be to Sections,
subsections, Exhibits and Schedules, respectively, of this Agreement unless otherwise specifically provided. 

        Section 7.12. Relationship of Parties.    Nothing contained in this Agreement shall be deemed or construed by the
parties, or by any third party, to create the relationship of partnership or joint venture between the parties hereto, it being understood and agreed that no provision contained herein shall be deemed
to create any relationship between the parties hereto other than the relationship of borrower and lender. 

        Section 7.13. Entire Agreement.    This Agreement and the Note set forth all of the promises, agreements, conditions and
understandings between the parties respecting the subject matter hereof and supersedes all negotiations, conversations, discussions, correspondence, memorandums and agreements between the parties
concerning the subject matter. 

        Section 7.14. Time of the Essence.    Time is of the essence with respect to this Agreement 

        IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written. 

	 	LENDER
	

 	

TRANSGENOMIC, INC., a Delaware corporation
	

 	

By	
 	

/s/  COLLIN J. D'SILVA      
 Collin J. D'Silva, President and Chief Executive Officer
	

 	

BORROWER
	

 	

GENODYSSEE S.A., a French société anonyme
	

 	

By	
 	

/s/  JEAN LOUIS ESCARY      
 Jean-Louis Escary, President du Conseil d'Administration

8

 
EXHIBIT A  

PROMISSORY NOTE  

	$1,500,000.00

February 1, 2002	Courtaboeuf, France

        For value received, the undersigned, GENODYSSEE S.A., a société anonyme formed under
the laws of France (herein, the "Maker") hereby promises to pay to the order of TRANSGENOMIC, INC., a corporation formed under the laws of the
State of Delaware, U.S.A. (hereinafter, the "Holder"), at any place designated at any time by the Holder, the principal sum of ONE MILLION FIVE HUNDRED
THOUSAND AND 00/100 DOLLARS ($1,500,000.00) (the "Principal Balance") on or before January 31, 2003. 

        This
Note is issued pursuant to that certain Term Loan Agreement, dated February 1, 2002, between the Maker and the Holder (the "Loan
Agreement"). All capitalized terms used and not otherwise defined shall have the meanings given them in the Loan Agreement. 

        The
Maker promises to pay the Principal Balance as set forth in the Loan Agreement. The Maker further promises to pay interest from the date hereof on the outstanding Principal Balance
at the rate set forth in the Loan Agreement. Interest shall be computed and payable as provided in the Loan Agreement. 

        If,
within 15 Business Days of a valid declaration by the Lender as set forth in the Loan Agreement, the relevant Event of Default has not been cured by the Borrower (if capable
of being cured), the Holder may, without notice or demand, declare the then outstanding Principal Balance and all outstanding interest immediately due and payable and shall then have in any
jurisdiction where enforcement hereof is sought, in addition to any other rights or remedies, the rights and remedies set forth in the Loan Agreement. 

        If
this Note is not paid as provided herein and in the Loan Agreement and is referred to an attorney for collection, the Maker promises to pay the reasonable and necessary fees and
expenses of such attorney, not to exceed US$50,000, in addition to the full amount due hereon, whether or not litigation is commenced. 

        Demand
for payment, protest, notice of dishonor and all other notices and demands under this Note and any and all lack of diligence in the enforcement of this Note are hereby waived by
the Maker, and the same hereby assents to each and every extension or postponement of the time of payment, at or after demand, or other indulgence, and hereby waive any and all notice thereof. 

        No
amendment, modification or waiver of any provision of this Note, nor consent to any departure by the Maker herefrom, shall be effective unless the same shall be in a writing signed by
an authorized officer of the Holder, and then only in the specific instance and for the purpose for which given. No failure to exercise, and no delay in exercising, any right under the Loan Agreement
or this Note shall operate as a waiver thereof, nor shall any single or partial exercise of any right under the Loan Agreement or this Note preclude any other or further exercise thereof or the
exercise of any other right. Each and every right granted hereunder or by law or in equity shall be deemed cumulative, and such remedies may be exercised from time to time concurrently or
consecutively. 

        All
notices required to be given or which may be given in connection with this Note shall be given in the manner required for notices under the Loan Agreement. 

        Any
term of this Note that does not comply with applicable law will not be effective if that law does not expressly or impliedly permit variations by agreement. If any part of this Note
cannot be enforced according to its terms, that fact will not affect the balance of this Note. 

9

 

        Neither
this Note nor the Maker's or Holder's rights and obligations under this Note are assignable or delegable without the prior written consent of the other as set forth in the Loan
Agreement. 

        This
Note will be governed by the laws of the State of New York. 

        IN
WITNESS WHEREOF, the Maker has executed and delivered this Note effective as of the date first set forth above. 

	 	GENODYSSEE S.A., a French société anonyme
	

 	

By	
 	

/s/  JEAN LOUIS EXCARY      
 Jean-Louis Escary, Président du conseil d'administration

10

 
EXHIBIT B  

SHAREHOLDERS' UNDERTAKINGS  

This
Agreement, dated as of February 1, 2002, is by and among: 

Jean-Louis Escary, born on **, a French citizen residing at ** 

Marie-Pierre Schmitz, born on **, a French citizen residing at **; 

Didier Lanson, born on **, a French citizen residing at **; 

Matignon Investissement et Gestion, a French limited company (société
anonyme) with a share capital of ** euros, having its registered office at 5, avenue Matignon, 75008 Paris (France) and registered with the  Registre du Commerce et des
Sociétés of Paris under number 404 380 305, acting in its name and for and on
behalf of the FCPR Matignon Investissements, a venture enterprise investment fund (governed by the Act of December 23, 1988), and represented by
Mr. de Massignac, its managing director; 

Société
Générale Asset Management, a French limited company (société
anonyme) with a share capital of ** euros, having its registered office at 2, place de la Coupole, 92400 Courbevoie (France) and registered with the  Registre du Commerce et des
Sociétés of Nanterre (France) under number 308 396 308, acting for and on behalf
of the FCPI SOGE Innovation, a venture capital investment fund, and represented by 

Société
Générale Asset Management, a French limited company (société
anonyme) with a share capital of ** euros, having its registered office at 2, place de la Coupole, 92400 Courbevoie (France) and registered with the  Registre du Commerce et des
Sociétés of Nanterre (France) under number 308 396 308, acting for and on behalf of the  FCPI SOGE Innovation 2, a venture capital investment fund, and
represented by 

Société
Générale Asset Management, a French limited company (société
anonyme) with a share capital of ** euros, having its registered office at 2, place de la Coupole, 92400 Courbevoie (France) and registered with the  Registre du Commerce et des
Sociétés of Nanterre (France) under number 308 396 308, acting for and on behalf of the  FCPI SGAM Innovation 1, a venture capital investment fund, and
represented by 

(hereinafter jointly referred to as the "Major Shareholders")  

AND  

TRANSGENOMIC, INC., a corporation organized under the laws of the State of Delaware U.S.A., with its registered office at
Omaha (Nebraska, U.S.A.), represented by Collin J. D'Silva, its President and Chief Executive Officer; 

(hereinafter referred as the "Lender")  

WITH THE PARTICIPATION OF  

GENODYSSEE S.A., a French limited company (société anonyme) with a share capital of **
euros, having its registered office at Parc Affaires Technopolis, 3, avenue du Canada, BP 810 Les Ulis, 91974 Courtaboeuf, France and registered with the Registre du Commerce
et des Sociétés of Evry under number 424 796 548, represented by Mr. Jean-Louis Escary, its  Président-Directeur Général;

(hereinafter referred as the "Company")  

 PREAMBLE  

WHEREAS,
pursuant to a certain Term Loan Agreement, dated as of even date herewith (the "Loan Agreement", capitalized terms used herein and not otherwise defined shall have the meanings assigned 

11

 

thereto in the Loan Agreement as in effect on the date hereof), by and among the Company and the Lender, the Lender has agreed to advance U.S. $1,500,000 to the Company; 

WHEREAS,
pursuant to Section 4.03 of the Loan Agreement, the Loan may be repaid by means of an issuance of shares of the Company; 

WHEREAS,
pursuant to Section 4.03 of the Loan Agreement, if a Qualified Offering is proposed prior the Maturity Date, the Company has agreed to use its commercially reasonable efforts
(i) to cause the capital increase required in order to issue securities to the Lender to be submitted to the vote of the shareholders of the Company at the same extraordinary general meeting as
the Qualified Offering and so (ii) to have such capital increase put on the agenda of such general meeting by its board of directors convening it and (iii) to have such capital increase
in favor of the Lender voted on by its shareholders in accordance with French law; 

WHEREAS,
pursuant to Section 4.03 of the Loan Agreement, in the event that a Qualified Offering is not consummated prior to the Maturity Date, the Company has agreed to use its commercially
reasonable efforts (i) to have an extraordinary general meeting convened by its board of directors prior the end of February 28, 2003 with a capital increase in favor of the Lender on
its agenda and (ii) to have the said capital increase in favor of the Lender voted on by its shareholders in accordance with French law; and 

WHEREAS,
at the date hereof, the Major Shareholders hold together 74.16% of the Company's share capital, it being understood by the parties hereto that the qualified majority required for a vote at an
extraordinary general meeting of the shareholders is 66.66% of such share capital; 

NOW,
THEREFORE, the Major Shareholders have agreed to make the following undertakings in order to ensure the affirmative vote of a capital increase in favor of the Lender under the conditions set
forth in Section 4.03 of the Loan Agreement. 

UNDERTAKINGS  

Section 1        A Qualified Offering is proposed prior to the Maturity Date  

If
a Qualified Offering is proposed prior the Maturity Date: 

(a)    each
Major Shareholder of the Company, on the condition that it is a member of the board of directors at that time, undertakes to use its commercially reasonable efforts to convene an
extraordinary general meeting of the shareholders of the Company so as to vote for a capital increase of the Company in order to issue new shares of the Company to the Lender in addition to the
capital increase with respect to the Qualified Offering; 

(b)    each
Major Shareholder of the Company, on the condition that it is a member of the board of directors at that time, undertakes to use its commercially reasonable efforts to put on the
agenda of the extraordinary general meeting of the shareholders which will vote the Qualified Offering a resolution with respect to the issuance of shares to the Lender in full repayment of the Loan
and a resolution with respect to the waiver by the existing shareholders of the Company of their preferential subscription right over these new shares, and; 

(c)    the
Major Shareholders undertake to vote in favor of such resolutions at such extraordinary general meeting convened by the board of directors in accordance with French law. 

Section 2        In the event that a Qualified Offering is not consummated prior to the Maturity Date  

In
the event that a Qualified Offering is not consummated prior to the Maturity Date: 

(a)    each
Major Shareholder of the Company, on the condition that it is a member of the board of directors on the Maturity Date, undertakes to use its commercially reasonable efforts to
convene prior 

12

 

the end of February 28, 2003 an extraordinary general meeting of the shareholders of the Company so as to vote for a capital increase of the Company in order to issue new shares of the Company
to the Lender; 

(b)    each
Major Shareholder of the Company, on the condition that it is a member of the board of directors on the Maturity Date, undertakes to use its commercially reasonable efforts to
put on the agenda of such an extraordinary general meeting of the shareholders a resolution with respect to the issuance of shares to the Lender in full repayment of the Loan and a resolution with
respect to the waiver by the existing shareholders of the Company of their preferential subscription right over these new shares; and 

(c)    The
Major Shareholders undertake to vote in favor of such resolutions at such extraordinary general meeting convened by the board of directors in accordance with French law. 

Section 3 Transferee or subscriber of newly issued shares  

No
Major Shareholder shall transfer its shares in the Company or approve the transfer of shares in the Company by another Major Shareholder (to the extent such approval is required) if such transfer
would cause the Major Shareholders collectively to hold less than the qualified majority required for a vote at an extraordinary general meeting of the shareholders of the Company, unless the
transferee of such shares agrees to enter into irrevocable undertakings identical to the shareholders' undertakings contained herein. 

Section 4 Shareholders' agreement  

Once
the Lender has been repaid by means of issuance of shares of the Company, the Major Shareholders undertake to use their commercially reasonable efforts to have the Shareholder's Agreement dated
September 8, 2000 amended in order to take into account the holding of the Lender, it being understood that the assent of all other parties thereto will also be required for such amendment of
the Shareholders' Agreement. 

MISCELLANEOUS  

Section 5 Governing Law  

These
undertakings shall be governed by and construed in accordance with French law. 

Section 6 Term and termination  

These
undertakings shall expire and be of no further effect or force upon the earlier of (ii) the Loan being repaid either in cash or in shares and (ii) the termination of the Loan
Agreement for any reason. 

IN
WITNESS WHEREOF, each the parties have caused this Agreement to be duly executed as of the day and year first above written. 

	/s/  JEAN LOUIS ESCARY      
 Jean-Louis Escary	 
	

/s/  MARIE PIERRE SCHMITZ      
 Marie-Pierre Schmitz	

 
	

/s/  DIDIER LANSON      
 Didier Lanson	

 
	

 	

 

13

 

	

Illegible
 Matignon Investissement et Gestion

Represented by	

 
	

Illegible
 FCPR Matignon Investissements

Represented by	

 
	

/s/  J. GRIMALIN      
 FCPI SOGE Innovation

Represented by J. Grimalin	

 
	

/s/  J. GRIMALIN      
 FCPI SOGE Innovation 2

Represented by J. Grimalin	

 
	

/s/  J. GRIMALIN      
 FCPI SGAM Innovation 1

Represented by J. Grimalin	

 
	

/s/  COLLIN J. D'SILVA      
 Transgenomic (the Lender)

Represented by Collin J. D'Silva,	

 
	

/s/  JEAN LOUIS ESCARY      
 Genodyssee (the Company)

represented by Jean-Louis Escary	

 

14

QuickLinks

Exhibit 10.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]